All‐cause mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV showed no clear difference in mortality compared with HAART alone (moderate certainty).
1 finding from 1 review
Kaposi's sarcoma IRIS · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + liposomal anthracycline showed no clear difference in kaposi's sarcoma IRIS compared with HAART alone (moderate certainty).
1 finding from 1 review
Progressive disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV probably leads to lower progressive disease compared with HAART alone (moderate certainty).
1 finding from 1 review
Clinical response ‐ complete response · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV showed no clear difference in clinical response ‐ complete response compared with HAART alone (moderate certainty).
1 finding from 1 review
Primary outcome: partial clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV probably leads to higher clinical response ‐ partial response compared with HAART alone (moderate certainty).
1 finding from 1 review
Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV probably leads to lower clinical response ‐ stable disease compared with HAART alone (moderate certainty).
1 finding from 1 review
Complete or partial remission · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV probably leads to higher clinical response ‐ overall response (complete and partial) compared with HAART alone (moderate certainty).
1 finding from 1 review
Adverse events · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV showed no clear difference in adverse events compared with HAART alone (moderate certainty).
1 finding from 1 review
Clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + pegylated liposomal doxorubicin showed no clear difference in clinical response compared with HAART alone (moderate certainty).
1 finding from 1 review
All‐cause mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + liposomal anthracycline showed no clear difference in mortality compared with HAART alone (moderate certainty).
1 finding from 1 review
Complete response · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete Response to Tx compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 6.54 [1, 42.86]
36 participants
Very low
Complete response plus partial response Length of · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete/Partial Response to Tx compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 1.47 [0.87, 2.49]
36 participants
Very low
Complete Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete Among Known Outcome compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 4.25 [0.7, 25.91]
30 participants
Very low
Complete/Partial Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete/Partial Among Known Outcome compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 1.01 [0.81, 1.27]
30 participants
Very low
All‐cause mortality · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes mortality compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 0.46 [0.29, 0.73]
98 participants
Very low
Intervention not reported
Objective response rate2 · Patients with advanced non‐small cell lung cancer
The intervention may leads to higher objective response rate2 (low certainty).
1 finding from 1 review
Parasitological failure at 1 month · People with S. mansoni infection
It is very uncertain whether artesunate (12 mg/kg) plus praziquantel (40 mg/kg) changes parasitological failure at 1 month compared with praziquantel (40 mg/kg) alone (very low certainty).
1 finding from 1 review
Requirement for anticholinergics number of participants requiring medication for extrapyramidal side effects · patients with an acute manic or mixed episode
Aripiprazole leads to higher requirement for anticholinergics number of participants requiring… compared with placebo (high certainty).
1 finding from 1 review
RR 3.28 [1.82, 5.91]
730 participants
High
Retention in treatment · patients with treatment of opioid dependence
Any Psychosocial intervention plus pharm showed no clear difference in retention in treatment Objective compared with pharm standard (high certainty).
1 finding from 1 review
Opioid abstinence objective · patients with treatment of opioid dependence
Any Psychosocial intervention plus pharm showed no clear difference in opioid abstinence objective compared with pharm standard (high certainty).
1 finding from 1 review